Rapid Response Of Treatment Resistant Polypoidal Choroidal Vasculopathy To Aflibercept Treatment

Abstract

Background: Polypoidal chorodial vasculopathy (PCV) is a disorder characterized by multiple, recurrent hemorrhagic exudative pigmented epithelium detachments and shows resistance to anti- photodynamic therapy (PDT) and anti-vascular endothelial growth factor (VEGF) treatment. In this case report, a rapid response to aflibercept treatment is presented. Case report: An anti-VEGF resistant PCV case showed rapid response to switching from bevacizumab to aflibercept in his right eye, and to primary treatment in left eye. Conclusion: Aflibercept can be more effective than other anti-VEGF agents and PDT in the treatment of PCV. Monthly aflibercept injection may be required rather than bimonthly regimen in resistant PCV cases.